Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

BUY
$0.14 - $12.49 $97,614 - $8.71 Million
697,245 New
697,245 $104,000
Q1 2022

May 12, 2022

SELL
$7.35 - $10.63 $53,552 - $77,450
-7,286 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$4.19 - $9.56 $20,618 - $47,044
4,921 Added 208.08%
7,286 $70,000
Q3 2021

Nov 12, 2021

SELL
$3.56 - $4.64 $3,916 - $5,104
-1,100 Reduced 31.75%
2,365 $11,000
Q2 2021

Aug 10, 2021

SELL
$3.95 - $5.41 $5,925 - $8,115
-1,500 Reduced 30.21%
3,465 $15,000
Q1 2021

May 12, 2021

BUY
$4.52 - $7.8 $22,441 - $38,727
4,965 New
4,965 $26,000
Q4 2020

Feb 10, 2021

SELL
$4.37 - $9.46 $437 - $946
-100 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$8.56 - $26.93 $856 - $2,693
100 New
100 $1,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.